Related to Seattle Genetics and OBT Establish Cancer Antibody-Drug Conjugate Collaboration

• YM BioSciences to Take Over Cytopia Gaining Base in Australia
  
• Spirogen Receives About $24M for Clinical-Stage Anticancer Drug and Reacquires Development Rights
  
• Transgenomic Licenses Cold-PCR Technology from the Dana-Farber Cancer Institute
  
• TargetEx Takes Over Coordinating European CancerGrid Project
  
• Serametrix Allies with Ludwig Institute to Exploit Tumor Antigens as Biomarkers
  
• BioTime Sets Up Subsidiary to Develop hESC-Based Therapies for Cancer
  
• Genetic Tech to Distribute Rosetta’s Cancer Tests in Australia, New Zealand, and Singapore
  
• GE and Lilly Develop Prototype to Visualize and Map Cancer Biomarker Networks
  
• GSK to Exploit SuperGen’s Epigenetics Expertise in Cancer Collaboration
  
• Scripps-Led Consortium that Combines Physics and Oncology Receives $10M
  
• Champions Biotechnology Gains Rights to Ramot’s Preclinical Anticancer Agent
  
• Micromet Obtains $11.84M Up Front in Cancer R&D Deal with Sanofi-Aventis
  
• Astex Signs CRADA with NCI to Investigate Its Small Molecule Therapeutic
  
• Boehringer Ingelheim Pledges $22.5M to Fund Another Four Years of Partnership with Evotec
  
• Gene Pinpointed that Could Negate Cancer Cells’ Ability to Repair Themselves
  
• Targeting a Tumor’s Microenvironment Could Be Used to Treat Cancer
  
• Bayer Decides to Investigate Compugen’s Newly Discover Cancer Targets
  
• Sangretech Gives Bostwick Scientific Rights to Its Dendritic-Cell Technology
  
• Oncodesign to Provide Sanofi-Aventis with Exclusive Cancer Models
  
• Novartis Signs Four-Year Deal with Horizon for Custom-Generated X-Man Cancer Models